MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Orosz, F.
Right arrow Articles by Ovadi, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orosz, F.
Right arrow Articles by Ovadi, J.

Functional in vitro test of calmodulin antagonism: effect of drugs on interaction between calmodulin and glycolytic enzymes

F Orosz, TY Christova and J Ovadi

Biological Research Center, Hungarian Academy of Sciences, Budapest.

A simple procedure has been elaborated to screen for the calmodulin antagonist effect of drugs. A covalently attached fluorescent probe was used to monitor the binding of enzymes known as target enzymes to calmodulin. Moreover, the probe made it possible to recognize a new target enzyme, aldolase (D-fructose-1,6-bisphosphate D-glyceraldehyde-3- phosphate-lyase, EC 4.1.2.13), for calmodulin among glycolytic enzymes. The calmodulin antagonist trifluoperazine prevented or eliminated the complex formation between calmodulin and enzymes studied in reconstituted systems; the Ca channel blockers had no effect. The functional consequences of the effect of drugs on calmodulin- phosphofructokinase (ATP:D-fructose-6-phosphate 1-phosphotransferase, EC 2.7.1.11) interaction were investigated as well. Whereas trifluoperazine suspended the calmodulin-mediated hysteretic inactivation of phosphofructokinase, Ca channel blockers (verapamil and nifedipine) were ineffective. Fendiline (regarded as a Ca channel blocker) seems to act as a functional calmodulin antagonist. Its binding to calmodulin does not prevent the complex formation of phosphofructokinase and calmodulin, but within this ternary complex phosphofructokinase preserves or recovers its original activity measured in the absence of calmodulin. The possible molecular effect of drugs on a calmodulin-enzyme complex is discussed.

Volume 33, Issue 6, pp. 678-682, 06/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B. Benziane, S. Demaretz, N. Defontaine, N. Zaarour, L. Cheval, S. Bourgeois, C. Klein, M. Froissart, A. Blanchard, M. Paillard, et al.
NKCC2 Surface Expression in Mammalian Cells: DOWN-REGULATION BY NOVEL INTERACTION WITH ALDOLASE B
J. Biol. Chem., November 16, 2007; 282(46): 33817 - 33830.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
I. Horvath, V. Harmat, A. Perczel, V. Palfi, L. Nyitray, A. Nagy, E. Hlavanda, G. Naray-Szabo, and J. Ovadi
The Structure of the Complex of Calmodulin with KAR-2: A NOVEL MODE OF BINDING EXPLAINS THE UNIQUE PHARMACOLOGY OF THE DRUG
J. Biol. Chem., March 4, 2005; 280(9): 8266 - 8274.
[Abstract] [Full Text] [PDF]

Home page
 Hum Exp ToxicolHome page
J-S Cheng, J-L Wang, Y-K Lo, K-J Chou, K-C Lee, C-P Liu, H-T Chang, and C-R Jan
Effects of the antianginal drug fendiline on Ca2+ movement in hepatoma cells
Human and Experimental Toxicology, July 1, 2001; 20(7): 359 - 364.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics